HitGen Inc.

HitGen Inc. (SSE: 688222.SH) offers drug discovery services built around its DNA-encoded library (DEL) technology, which it has extended into fragment-based drug discovery (FBDD), structure-based drug design (SBDD), and related platforms.

Services and capabilities

• DEL design, synthesis, and screening, including DEL selection on targets such as PPIs, kinases, GPCRs, and RNA
• FBDD/SBDD, including off-rate screening and structure-based design
• Medicinal chemistry, synthetic and high-throughput chemistry, and analytical chemistry and quality research
• Oligonucleotide services, including nucleic acid sequence design, monomer and solid support chemistry, and oligonucleotide CDMO
• Biology support, including protein science, NGS and bioinformatics, cell biology, pre-clinical studies, and bioanalysis
• Computational chemistry and informatics

Engagement models

HitGen describes its business as technical services, project out-licensing, and product sales, and says it has worked with over 600 clients as of the end of 2025. Its services page describes comprehensive drug discovery support spanning hit identification, hit-to-lead, lead optimization, preclinical studies, and IND filing.

Platforms and locations

The company's HAILO platform combines DEL, AI, and automation for molecular optimization. HitGen is headquartered in Chengdu, China, and has subsidiaries in Cambridge, UK, and Houston, USA.

HitGen also advances internal programmes at clinical and preclinical stages.